Shares of HIMS experienced a dramatic slump today following the unexpected cancellation of its partnership with pharmaceutical giant Novo Nordisk. Investors reacted negatively to the news, sending HIMS's stock price plummeting by nearly 20%. The reason for the dissolution of the partnership remains